

Rec'd PCT/PTO 02 MAR 2006

29 Hartwell Avenue, Lexington, MA 02421  
Tel: 781.674.7000  
Fax: 781.863.6519

**TransForm  
Pharmaceuticals, Inc.**

# Fax

To: Barbara Campbell

From: Paul Burgess, Esq.

United States Patent and Trademark Office

Fax: (571) 273-9886

Pages: 3

Phone:

Date: March 2, 2006

Re: U.S. Application Serial No. 10/541,216

CC:


☒ For Review☐ Please Comment☐ Please Reply☐ Please Recycle

Dear Ms. Campbell:

As a follow up to our discussion yesterday and in response to the attached *Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures* dated 02/23/2006, please note that this application does not contain a sequence listing. I believe that this notice was therefore mailed in error.

Thank you for your attention to the above. Should you have any questions, please do not hesitate to contact me directly at #(781) 674-7816.

Regards,



Paul Burgess  
Patent Attorney  
Reg. No. 53,852

CERTIFICATE OF FACSIMILE

I hereby certify that this correspondence is being transmitted via facsimile to #(571) 273-9886 at the United States Patent and Trademark Office on March 2, 2006.

Signed:

  
Kristin Miele

THE INFORMATION CONTAINED IN THIS COMMUNICATION IS CONFIDENTIAL, MAY BE ATTORNEY-CLIENT PRIVILEGED, AND IS INTENDED ONLY FOR THE USE OF THE ADDRESSEE. UNAUTHORIZED USE, DISCLOSURE OR COPYING IS STRICTLY PROHIBITED AND MAY BE UNLAWFUL. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE IMMEDIATELY NOTIFY THE SENDER BY PHONE AT #(781) 674-8000 OR BY FACSIMILE AT (781) 863-6519.



UNITED STATES PATENT AND TRADEMARK OFFICE

 UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/541,216	Mark Tawa	TPIP017DWO US

INTERNATIONAL APPLICATION NO.
-------------------------------

PCT/US03/41273

I.A. FILING DATE	PRIORITY DATE
------------------	---------------

12/24/2003

12/30/2002

27777

 PHILIP S. JOHNSON  
 JOHNSON & JOHNSON  
 ONE JOHNSON & JOHNSON PLAZA  
 NEW BRUNSWICK, NJ 08933-7003

RECEIVED

MAR 01 2006

CONFIRMATION NO. 4554

J&amp;J PAT. DKT. SECTION 571 FORMALITIES LETTER



\*OC000000018057840\*

Date Mailed: 02/23/2006

### NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c). Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 8 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patent Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

MAR-02-2006 THU 10:34 AM

FAX NO. **Rec'd PCT/PTO 02 MAR 2006**

Page 2 of 2

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

**PART 1 - ATTORNEY/APPLICANT COPY**

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/541,216	PCT/US03/41273	TPIP017DWO US

FORM PCT/DO/EO/922 (371 Formalities Notice)